Broadcom, Eli Lilly and Trump Media rise premarket; Under Armour falls

June 24, 2024 09:22 PM AEST | By Investing

Google News:

Broadcom, Eli Lilly and Trump Media rise premarket; Under Armour falls

Recent News

Avoiding Grid Outages With Network Digital Twins

AppLovin would be more valuable without its 1P games, Morgan Stanley a...

Morgan Stanley downgrades Lululemon on weak US growth outlook

Canada to hit NATO defense target early - The Globe and Mail

Investing.com -- U.S. stock futures edged mostly higher Monday, with activity limited ahead of the release of key inflation data later in the week.

Here are some of the biggest premarket U.S. stock movers today:

Apple (NASDAQ:AAPL) stock rose 0.3% despite the European Commission saying Monday the iPhone maker's App Store rules breach EU tech rules because they prevent app developers from steering consumers to alternative offers.
Broadcom (NASDAQ:AVGO) stock rose 0.6% after Reuters reported that the chipmaker is working with Chinese technology firm ByteDance to develop an advanced artificial intelligence processor, even as the U.S. is attempting to restrict the export of these vital chips to its main economic rival.
Nvidia (NASDAQ:NVDA) stock fell 1.8%, continuing the selloff seen late last week after the chipmaker briefly became the most valuable company in the world.
United Parcel Service (NYSE:UPS) stock rose 0.2% after the world's biggest package delivery firm announced it will sell its Coyote Logistics business unit to RXO (NYSE:RXO), up 14%, for $1.025 billion.
Eli Lilly (NYSE:LLY) stock rose 1% after the drugmaker said that its weight-loss drug Zepbound resolved sleep apnea in up to 52% of patents.
Trump Media & Technology (NASDAQ:DJT) stock rose 6.3%, with the former president’s media company rebounding after a week-long selloff.
Under Armour (NYSE:UA) stock fell 2.3% after the sports apparel maker said it has agreed to pay $434 million to settle a 2017 class action lawsuit accusing the company of defrauding shareholders.
ResMed (NYSE:RMD) stock fell 12% after results over the weekend from a weight-loss drug trial raised doubts about the sleep apnoea treatment provider’s key market.

This article first appeared in Investing.com

Disclaimer

The content, including but not limited to any articles, news, quotes, information, data, text, reports, ratings, opinions, images, photos, graphics, graphs, charts, animations and video (Content) is a service of Kalkine Media Pty Ltd (“Kalkine Media, we or us”), ACN 629 651 672 and is available for personal and non-commercial use only. The principal purpose of the Content is to educate and inform. The Content does not contain or imply any recommendation or opinion intended to influence your financial decisions and must not be relied upon by you as such. Some of the Content on this website may be sponsored/non-sponsored, as applicable, but is NOT a solicitation or recommendation to buy, sell or hold the stocks of the company(s) or engage in any investment activity under discussion. Kalkine Media is neither licensed nor qualified to provide investment advice through this platform. Users should make their own enquiries about any investments and Kalkine Media strongly suggests the users to seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice), as necessary.
The content published on Kalkine Media also includes feeds sourced from third-party providers. Kalkine does not assert any ownership rights over the content provided by these third-party sources. The inclusion of such feeds on the Website is for informational purposes only. Kalkine does not guarantee the accuracy, completeness, or reliability of the content obtained from third-party feeds. Furthermore, Kalkine Media shall not be held liable for any errors, omissions, or inaccuracies in the content obtained from third-party feeds, nor for any damages or losses arising from the use of such content.
Kalkine Media hereby disclaims any and all the liabilities to any user for any direct, indirect, implied, punitive, special, incidental or other consequential damages arising from any use of the Content on this website, which is provided without warranties. The views expressed in the Content by the guests, if any, are their own and do not necessarily represent the views or opinions of Kalkine Media. Some of the images/music that may be used on this website are copyrighted to their respective owner(s). Kalkine Media does not claim ownership of any of the pictures displayed/music used on this website unless stated otherwise. The images/music that may be used on this website are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have made reasonable efforts to accredit the source wherever it was indicated as or found to be necessary.
This disclaimer is subject to change without notice. Users are advised to review this disclaimer periodically for any updates or modifications.